1. Structural Information of Calreticulin {#sec1}
=========================================

Calreticulin (CRT) is a 46 KDa multifunctional protein predominantly located in endoplasmic reticulum (ER) and highly conserved in diverse species. It is synthesized with a cleavable signal sequence at N-terminal and an ER KDEL (Lys-Asp-Glu-Leu) retrieval signal at C-terminal. Structural predictions of CRT demonstrated that the protein is composed of three domains, including N-domain, P-domain, and C-domain ([Figure 1](#fig1){ref-type="fig"}) \[[@B1]\].

The N-terminal region of CRT is a globular domain containing eight antiparallel *β*-strands \[[@B2]\]. This domain can interact with *α*-integrins \[[@B3]\] and DNA-binding site of steroid receptor \[[@B4]\]. The disulfide bond formed by cysteine residues in the N-domain may interact with P-domain to generate important chaperone function of calreticulin \[[@B5]\].

The proline-rich P-domain contains two sets of three repetitive regions \[[@B6]\]. These repeated amino acid sequences form the lectin-like chaperone structures which are responsible for protein-folding function of CRT. Moreover, the P-domain of CRT is also a high-affinity and low-capacity Ca^2+^-binding region \[[@B7], [@B8]\].

The C-domain of CRT is a highly acidic region which is important for Ca^2+^-buffering functions. It binds to Ca^2+^ with high capacity and low affinity manner \[[@B9]\]. It is known that Ca^2+^ binding to this region plays a critical role in the interaction with other chaperone proteins in ER \[[@B1], [@B10]\].

Since there is a KDEL sequence for retrieval in the ER at C-terminal of CRT, it is not surprising that this protein is highly enriched within the ER lumen. However, evidences demonstrated that CRT is also expressed in cytosol \[[@B11]\] and on cell surface \[[@B12]\]. It has been reported that the C-domain is important for CRT retrotranslocation from ER lumen to the cytosol \[[@B13]\]. Further study also indicates that this retrotranslocation process is triggered by ER Ca^2+^ depletion \[[@B14]\]. In addition, some studies have shown that cytoplasmic CRT may interact with the cytoplasmic tail of *α*-integrin through the KXGFFFKR sequences \[[@B3], [@B15]--[@B17]\]. Furthermore, cell surface CRT is associated with phagocytic uptake and immunogenicity of cells \[[@B18]\]. These results provide more evidences for CRT as a multifunctional protein which may participate in various physical and pathological events in cells.

2. Biological Functions of Calreticulin {#sec2}
=======================================

Over the past years, CRT has been proposed to participate in various physiological and pathological processes in cells. The two major functions of CRT inside the ER are protein chaperoning and regulation of Ca^2+^ homeostasis. Furthermore, accumulated studies indicate that non-ER CRT also regulates important biological functions including cell adhesion, gene expression, and RNA stability.

3. Protein Chaperone {#sec3}
====================

ER is an important organelle for synthesis, folding, and transportation of secretory proteins. These functions are carried out by molecular chaperones which facilitate correctly protein folding and assembly. CRT is one of the well-characterized lectin-like ER chaperons for many proteins \[[@B19]--[@B22]\]. Recent evidences indicated that CRT is involved in quality control process during protein synthesis, including integrins, surface receptors, and transporters \[[@B1]\].

4. Calcium Homeostasis {#sec4}
======================

Ca^2+^ is mainly stored in ER lumen and is a universal signaling molecule affecting many developmental and cellular processes \[[@B23]\]. Numerous reports indicated that Ca^2+^-binding chaperones influence Ca^2+^ storage capacity in the ER lumen \[[@B24]--[@B27]\]. CRT is considered as an intracellular Ca^2+^ regulator since it contains two Ca^2+^-binding sites in the P-domain (high-affinity, low-capacity) and C-domain (low-affinity, high-capacity) \[[@B7], [@B9]\]. More than 50% of Ca^2+^ stored in ER lumen associates with CRT \[[@B9]\]. Therefore, higher levels of CRT may lead to increase intracellular Ca^2+^ storage \[[@B28], [@B29]\]. In contrast, CRT-deficient cells have a lower capacity for Ca^2+^ storage in the ER lumen \[[@B9]\]. The cardiac development in CRT-deficient mice is defective due to the impaired Ca^2+^ homeostasis of CRT \[[@B30], [@B31]\]. Besides, abnormal function of CRT also associated with adipocyte differentiation and Henle\'s loop adaptation under osmotic stress \[[@B32], [@B33]\]. These findings further support that CRT plays crucial roles during Ca^2+^ homeostasis.

5. Cell Adhesion {#sec5}
================

The concept that CRT might be involved in cell adhesion is based on the regulation of focal contact via multiple mechanisms \[[@B34], [@B35]\]. It is clear that the extracellular matrix (ECM) molecules are important for focal contact formation. Several studies elucidated that alteration of CRT levels affects cell adhesion on various ECM \[[@B36]--[@B38]\]. Papp et al. implicated that CRT plays a role in the control of cell adhesiveness through regulation of fibronectin expressions and matrix deposition. These effects are mediated via Ca^2+^-dependent effect of CRT on c-SRC activity \[[@B39]\]. In addition, previous studies revealed that CRT-mediated cell adhesion might be due to direct interaction between CRT and integrins by binding to the cytoplasmic KXGFFKR motif of the integrin *α*-subunit \[[@B3], [@B40], [@B41]\]. These studies provided evidences that CRT plays a critical role in cellular adhesiveness.

6. RNA Stability {#sec6}
================

In 2002, Nickenig et al. first indicated CRT as a novel mRNA binding protein that destabilizes type I angiotensin II receptor mRNA by binding to AU-rich region in 3′-UTR \[[@B42]\]. Moreover, Totary-Jain et al. reported that CRT also binds to specific element in 3′-UTR of glucose transporter-1 mRNA and destabilizes the mRNA under high-glucose conditions \[[@B43]\]. These results identified a new function of CRT which is being a trans-acting factor which regulates mRNA stability.

7. Regulation of CRT Expression {#sec7}
===============================

The human calreticulin gene (*CALR*) is located on chromosome 19p13.2 with nine exons. Calreticulin promoter region contains several binding sites for reputed transcription factors and many of these factors have been identified as important modulators of CRT expression including NKx2.5, MEF2C, COUP-TF1, GATA6, Evi-1, and PPAR factors \[[@B44]\]. In addition, calcium depletion and ER stress were shown to be important activators of*CALR* transcription \[[@B45]\]. Recently, studies have also revealed that nerve growth factor (NGF) can also upregulate CRT expression in both ovarian cells and neuronal differentiation \[[@B46], [@B47]\]. These results suggested an involvement of CRT expression in various biological and pathological processes.

8. Clinical Impacts of Calreticulin Expression in Different Cancers {#sec8}
===================================================================

The correlation between CRT expression levels and tumorigenesis has been extensively studied in various cancers and most reports have indicated that tumor tissues express significant higher levels of CRT compared to normal tissues \[[@B48]\]. These clinicopathological significances for CRT in different cancers are summarized in [Table 1](#tab1){ref-type="table"}. Studies have demonstrated that the CRT expression levels were positively correlated with clinical stages and lymph node metastasis in gastric cancer \[[@B49]\] and breast cancer \[[@B50]\]. In addition, patients with higher CRT levels had a poor survival rate in pancreatic cancer and esophageal squamous cell carcinoma \[[@B52], [@B51]\]. Other studies also revealed CRT expression levels to be significantly upregulated in oral cancer \[[@B53]\], breast ductal carcinoma \[[@B54], [@B55]\], colorectal cancer \[[@B56]\], prostate cancer \[[@B57]\], and vaginal carcinoma \[[@B58]\]. Furthermore, CRT levels not only increase in bladder cancer tissues \[[@B59]\], and urinary CRT has also shown to be a useful biomarker for bladder urothelial cancer detection \[[@B60]\]. Kageyama et al. implicated that the concentration of urinary CRT has a tendency to increase in high grade tumors \[[@B61]\]. These results indicate that increased CRT expression might play a crucial role during cancer progression.

On the other hand, the roles of CRT in ovarian cancer progression are inconclusive. Compared with primary tumors and solid metastases, reduced CRT expression was observed in malignant effusions of high-grade ovarian carcinoma along disease progression \[[@B62]\]. Moreover, CRT expression levels in effusions may be associated with better response to chemotherapy while the survival was not related to CRT expression \[[@B62]\]. Furthermore, in neuroblastoma, increased CRT expression is found to be associated with better prognosis and differentiated histologies \[[@B63], [@B64]\]. Therefore, the impact of CRT on tumor formation and progression may depend on different cell types and clinical stages.

Very recently, mutations in calreticulin gene were detected in myeloproliferative neoplasms (MPN) \[[@B65], [@B66]\]. Most patients with MPN including polycythemia vera (PV), essential thrombocythemia (ET), and primary myelofibrosis (PMF) were found to have mutations in Janus kinase 2 gene (JAK2) \[[@B67], [@B68]\]. For the remaining patients, mutations in CRT gene were identified \[[@B65], [@B66]\]. These CRT mutations include 52 bp deletion and 5 bp insertion of certain base pairs, which leads to frameshift mutations \[[@B69]\]. Proteins encoded by mutated CRT gene lack the C-terminal KDEL domain; therefore they may affect normal Ca^2+^ binding and cell growth.

9. Membrane Calreticulin as a Phagocytic Signal {#sec9}
===============================================

An important role for CRT exposed on the cell surface, which is relevant for destruction of cancer cells, is via induction of the immune response \[[@B18], [@B70]\]. Results from several laboratories have demonstrated that cell surface CRT facilitates the phagocytic uptake of apoptotic and cancer cells \[[@B71]--[@B73]\]. Clarke and Smyth demonstrated that drug treatments (anthracyclines) caused tumor cell to expose a surface prophagocytic protein, CRT, which induced immunogenic cell death \[[@B74]\]. Additionally, suppression of CRT by siRNA inhibited the anthracycline-induced phagocytosis by dendritic cells and destroyed their immunogenicity in mice \[[@B72]\]. It is becoming clear that surface exposure of CRT is required for phagocytosis on dying tumor cells. CRT expressed on the cell surface is considered as an "eat-me" signal for multiple human cancers, and this prophagocytic function of CRT is disrupted by an antiphagocytic signal CD47 \[[@B71]\]. It has been previously described that an antiphagocytic signal CD47 was increased with high amounts of CRT on cancer cell surfaces to avoid phagocytosis by the immune system \[[@B73]\]. Therefore, interruption of the ability of CD47 by anti-CD47 antibodies might have a therapeutic effect to enhance cancer cell phagocytic uptake \[[@B18]\]. Taken together, these results indicate that CRT-mediated immune mechanisms might be an important strategy for developing new anticancer therapy.

Another interesting question is how this ER chaperone protein gets out of the cell. Several possible mechanisms have been discussed previously \[[@B18], [@B25], [@B70]\]. Studies revealed that CRT cotranslocates to the cell surface with ERp57 after anthracycline treatment dictates the immunogenic cell death in preapoptotic cells \[[@B70], [@B76]--[@B78]\]. The exposure pathway of CRT/ERp57 complex is suggested to be triggered by provoking the reactive oxygen species (ROS) or ER stress that activates pancreatic ER kinase (PERK). Activated PERK leads to phosphorylation of the eukaryotic translation inhibition factor eIF2*α*, followed by preapoptotic cleavage of caspase 8 and activation of Bax and Bak \[[@B76], [@B79]\]. Interestingly, recent studies indicated that ER calcium levels were also involved in CRT translocation to cell surface. Thapsigargin treatment, which leads to ER Ca^2+^ depletion, elevates cell surface expression and secretion of CRT protein \[[@B80]\]. In addition, some chemotherapeutic agents, such as anthracyclines, could also affect the translocation of CRT to the cancer cell surface \[[@B81]\]. CRT expressed on cancer cell surface is important for activation of immune responses. Increasing cell surface CRT exposure may be a potential strategy to develop therapeutics to kill cancer cells.

10. Functions of Calreticulin in Regulating Cancer Cell Proliferation {#sec10}
=====================================================================

Cancer formation is characterized by rapid proliferation of mutated cells. Many studies have elucidated that manipulation of CRT levels had profound effects on tumor cell proliferation in diverse types of cancer cells. In pancreatic cells, overexpressed CRT enhanced cell growth; in contrast, knockdown of CRT had the opposite effect on cell growth \[[@B51]\]. In addition, depletion of CRT caused cell cycle arrest at the G0/G1 phase which resulted in significantly suppressed growth rate, colony-formation capacity, and anchorage-independent growth in oral cancer cell \[[@B53]\]. Importantly, Chen et al. have reported that higher levels of CRT promoted cell proliferation and upregulated the proangiogenic factor vascular endothelial growth factor (VEGF) expression in gastric cancer cells \[[@B49]\]. The role of VEGF in regulating angiogenesis has been well documented \[[@B82], [@B83]\]. As secreted by tumor cells, VEGF binds to specific receptors and activates downstream signal pathways including the mitogen-activated protein kinase (MAPK) and the Ras/extracellular signal-regulated kinase (ERK) which promotes cell proliferation, survival, migration, and angiogenesis \[[@B84], [@B85]\]. We also found that knockdown of CRT suppressed cell growth in bladder cancer \[[@B36]\]; therefore, we further investigated whether levels of VEGF were also affected by CRT in bladder cancer cells. Results shown in [Figure 2](#fig2){ref-type="fig"} indicated that both expression and secretion levels of VEGF were decreased in CRT-knockdown bladder cancer cells. Although many reports have indicated that CRT has a positive effect on cell growth, other studies provided different viewpoints on this issue. A recent study demonstrated that prostate cancer cells with higher CRT levels produced fewer colonies as well as inhibition of tumor growth both*in vitro* and*in vivo* \[[@B86]\]. Moreover, vasostatin, a fragment of CRT, is considered as an antiangiogenic factor and inhibits VEGF-induced endothelial cell proliferation \[[@B87]\]. Our recent study also demonstrated that CRT upregulates VEGF expression, suppresses cell proliferation, and enhances cell differentiation in neuroblastoma cells \[[@B88]\]. These results strongly suggested that effect of CRT on cell proliferation might depend on cell types.

11. Roles of Calreticulin in Neuronal Differentiation in Neuroblastoma {#sec11}
======================================================================

Neuroblastoma (NB) is the most frequently diagnosed malignancy in infancy, with more than 96% of patients diagnosed at the age of \<10 years \[[@B89], [@B90]\]. It is derived from the sympathoadrenal lineage of embryonic neural crest cells \[[@B91]\]. Previous studies suggest that incomplete development and failure of differentiation or apoptosis of neuroblastic cells is critical in its development \[[@B92]\]. Previous studies have shown that NB cells exhibit a capacity of differentiating into mature cells or spontaneous regression by apoptosis \[[@B93], [@B94]\]. Studies also demonstrated that NB can be forced to differentiate upon the treatment of retinoic acid \[[@B95]\]. On the other hand, NB with better prognosis often express molecular markers indicative of cell differentiation, such as TrkA \[[@B96]\]. Furthermore, the expressions of apoptosis-related genes including p53, Bcl-2, and Bax have been demonstrated in NB and are correlated with favorable prognosis \[[@B97]\]. In some cancers, CRT is found to be upregulated in tumor tissues compared to normal tissue. Conversely, in NB, increased CRT expression is associated with better prognosis and differentiated histologies both*in vitro*and*in vivo* \[[@B63], [@B64]\]. A CRT knockout (KO) mouse model exhibited embryonic lethality with significant defects in heart, brain, and body wall, suggesting an essential role of CRT in the embryonic development of nervous system \[[@B98]\]. It has been reported that surface CRT is crucial for neurite formation \[[@B99]\]. Moreover, a recent study using PC-12 cells expressing mutant CRT lacking a Ca^2+^-buffering domain (C-domain) suggested that the Ca^2+^-regulating capacity of CRT is essential for NGF-elicited neuronal differentiation \[[@B47]\]. Our recent studies further demonstrated that CRT could suppress cell proliferation and enhance cell differentiation, whereas apoptosis was not altered in NB cells, implying CRT as an important favorable prognostic factor in NB \[[@B88]\]. Besides, we showed that blockage of VEGF signaling could suppress neuronal differentiation in CRT-overexpressed NB cells, suggesting that VEGF-A is involved in CRT-related neuronal differentiation in NB. These results clearly delineate a novel mechanism of CRT during tumorigenesis of NB \[[@B88]\]. These findings also suggest that CRT plays an important role in neuronal differentiation.

12. Roles of Calreticulin in Cell Migration and Adhesion {#sec12}
========================================================

Metastasis is a critical event for cancer progression. This mechanism involves many processes, including cell adhesion, migration, and invasion. Previous studies have revealed that overexpressed CRT contributes to cancer metastasis in gastric, pancreatic, prostate, and ovarian cancers \[[@B51], [@B49], [@B62], [@B100]\]. The possible mechanisms for CRT-mediated cell migration or adhesion have been intensively investigated. One suggested mechanism is that CRT is one of the few cytoplasmic proteins that directly interact with integrin *α*-subunits \[[@B15], [@B17]\]. In 1995, Coppolino et al. have shown that the interaction between integrin *α*2*β*1 and CRT can be stimulated by integrin activation \[[@B103]\]. They further used the PC-3 prostate cancer cell line as a model to demonstrate that the interaction between integrins and CRT is modulated by phosphorylation and dephosphorylation status \[[@B104]\]. A recent study also reported that integrin-dependent cell adhesion on fibronectin was apparently affected when CRT is overexpressed in epithelial-mesenchymal transition- (EMT-) like cells \[[@B105]\].

Other mechanisms have also proposed that CRT modulates cell adhesion and migration through focal contact dependent manners \[[@B34]\]. This theory is further supported by different levels of CRT affects ECM expressions \[[@B39]\]. Manipulation of CRT expression in mouse L fibroblasts has had a profound effect on fibronectins synthesis. These effects might be due to regulation of c-SRC activity \[[@B39]\]. Cells with higher levels of CRT exhibited increased adhesiveness ability, which is relevant for the calmodulin/calmodulin-dependent kinase II pathway \[[@B106]\]. Moreover, CRT has been reported as a positive regulator for another important focal contact molecule, vinculin. Upregulation of CRT enhanced cell adhesiveness and cell spreading, while knockdown of CRT showed inverse effects in L fibroblast cells \[[@B38]\]. Furthermore, cell surface CRT interacted with thrombospondin to modulate focal adhesion disassembly through the PI3-kinase-dependent pathway \[[@B108]\]. Evidence from these studies suggested that CRT plays a critical role in regulating cell adhesion and migration via various mechanisms.

13. New Insight of Calreticulin in Regulation of Integrin Activity {#sec13}
==================================================================

Integrins are heterodimeric transmembrane receptors composed of *α*- and *β*-subunits. They connect extracellular matrix and intracellular cytoskeleton by several cytoplasmic binding proteins to control cell adhesion and migration processes \[[@B109]\]. As we mentioned in previous sections, CRT has been characterized as an intracellular integrin *α*-subunit binding protein and it is essential for integrin-mediated cell adhesion \[[@B15], [@B17]\]. Meanwhile, little is known about how this mainly ER-resident protein can modulate cell surface receptor functions. According to our latest observation, one critical role of CRT which regulates integrin activation is through modifying *α*1, 2-linkaged glycomic status on *β*1-integrin. Mechanistic investigation demonstrated that CRT controlled the mRNA stability of an important enzyme, fucosyltransferase 1 (FUT1), which catalyzes *α*1, 2-linked fucosylation on *β*1-integrin and subsequently promotes *β*1-integrin activities \[[@B110]\]. These results not only clarify the biological mechanism for CRT regulating integrin functions in cell adhesion process but also provide a new possible strategy for inhibition of cancer metastasis.

14. Concluding Remarks {#sec14}
======================

In this review, we summarized the evidences for CRT effects on cancer development. Notably, abnormal CRT levels are highly correlated with pathological outcomes in different types of cancers. Extensive evidences have shown that CRT participates in varieties of cellular functions both inside and outside of ER lumen. The two major functions of CRT are protein chaperoning and Ca^2+^ homeostasis, while mounting evidences indicate that non-ER CRT also plays a crucial role during tumor development. One of the important CRT-mediated mechanisms which regulated cancer cell adhesion is through interaction with integrins. As well as connecting to extracellular matrix, activation of integrins impacts cytoskeletal dynamic by various integrin cytoplasmic-binding proteins \[[@B109], [@B111]\]. Recently, CRT is known as an integrin *α*-subunit binding protein and it can facilitate *β*1-integrin activation through influencing integrin glycosylation by FUT1 levels. Taking this into consideration, it will be crucial to understand how CRT regulates cell adhesion. It still remained unclear how CRT levels were stimulated in different cancer. Future studies should be required to delineate the possible upstream signal of CRT-related cancer progression, and these results will decipher the roles of CRT in cancer biology.
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![The protein structure and putative functions of calreticulin domains. The figure represents a schema of calreticulin. The protein contains three functional domains: N-domain, P-domain, and C-domain. There is a signal sequence at N-terminal and a KDEL ER retrieval peptide at C-terminal. The two sets of repeated regions are indicated by triangles and squares, respectively. The putative functions of each domain as shown.](BMRI2015-526524.001){#fig1}

![Knockdown of calreticulin suppressed VEGF-A mRNA expression and protein secretion in bladder cancer cell. Details on CRT-knockdown human bladder cancer cell lines (control and CRT-RNAi) were described previously \[[@B36]\]. (a) Real-Time PCR was used to detect VEGF-A mRNA levels in J82 control and CRT-knockdown cells. Total RNA was isolated by the TRIzol reagent following the manufacturer\'s instructions. Reverse transcription PCR was carried out using ReverTra Ace reverse transcriptase. Real-Time PCR was performed using the iCycler iQ Real-Time detection system (Bio-Rad, Hercules, CA) with the DNA double-strand specific SYBR Green I dye for detection. RNA expression was normalized to the internal control, GAPDH. (b) VEGF-A secretion levels were detected by enzyme-linked immunosorbent assay (ELISA) in conditioned media of J82 control and CRT-knockdown cells. Cells were plated at 5 × 10^5^ cells/well in six-well plates. Conditioned media were collected and analyzed using an ELISA kit specific for human VEGF (BioSource, Camarillo, CA, USA). Statistical differences were compared to the control level (^\*^ *P* \< 0.05, ^\*\*\*^ *P* \< 0.001).](BMRI2015-526524.002){#fig2}

###### 

Expression of CRT in different cancers.

  Cancer              CRT levels^\*^   Clinical outcomes                                                        Reference
  ------------------- ---------------- ------------------------------------------------------------------------ --------------------
  Oral                Increased        ---                                                                      \[[@B53]\]
  Esophagus           Increased        ↓ survival (poor prognosis)                                              \[[@B52]\]
  Breast              Increased        ↑ metastasis, ↑ invasion, ↓ survival                                     \[[@B50]--[@B55]\]
  Pancreas            Increased        ↑ lymph node metastasis, ↑ UICC stage, ↓ survival                        \[[@B51]\]
  Gastric             Increased        ↑ lymph node metastasis, ↑ invasion, ↑ microvessel density, ↓ survival   \[[@B49]\]
  Colon               Increased        ---                                                                      \[[@B56]\]
  Bladder             Increased        ↑ urinary CRT, ↑ histological grade, ↑ pathological T stage              \[[@B59]--[@B61]\]
  Prostate            Increased        ---                                                                      \[[@B57]\]
  Vagina              Increased        ---                                                                      \[[@B58]\]
  ^\#^Ovarian         Increased        Better response to chemotherapy                                          \[[@B58], [@B62]\]
  ^\#^Neuroblastoma   Increased        ↑ differentiation, ↑ survival                                            \[[@B63]\]

↑: increased; ↓: decreased.

^\*^CRT levels in tumor tissue except ovarian carcinoma in effusion fluids.

^\#^Higher levels of CRT seem to correlate with good prognosis for the diseases.
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